Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) EPS (Basic) (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has 6 years of EPS (Basic) data on record, last reported at -$0.44 in Q4 2020.

  • For Q4 2020, EPS (Basic) fell 2.33% year-over-year to -$0.44; the TTM value through Dec 2020 reached -$1.88, down 2.17%, while the annual FY2025 figure was -$3.29, 11.56% up from the prior year.
  • EPS (Basic) reached -$0.44 in Q4 2020 per SNDX's latest filing, up from -$0.46 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.79 in Q1 2018 and bottomed at -$5.13 in Q4 2018.
  • Average EPS (Basic) over 5 years is -$0.82, with a median of -$0.47 recorded in 2016.
  • The widest YoY moves for EPS (Basic): up 257.45% in 2018, down 541.25% in 2018.
  • A 5-year view of EPS (Basic) shows it stood at -$0.59 in 2016, then tumbled by 35.59% to -$0.8 in 2017, then plummeted by 541.25% to -$5.13 in 2018, then surged by 91.62% to -$0.43 in 2019, then fell by 2.33% to -$0.44 in 2020.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.44 in Q4 2020, -$0.46 in Q3 2020, and -$0.42 in Q2 2020.